Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

But just seven years ago, and despite living with HIV for nearly half his life, Duffy was remarkably healthy, working in ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Discover the latest advancements in HIV prevention and how they offer hope for reducing infections, especially in the Black ...

Although the association between HIV and long COVID was inconclusive, the prevalence of long COVID in patients with HIV was ...

Here are some of the findings from UNAIDS' new report on HIV and human rights, and what they could mean for the fight against ...

CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...

The government provides HIV medicines free of charge. Yet in one Indigenous territory, cases and deaths are increasing at an ...

Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...

Among treatment-naive people with HIV, dolutegravir/lamivudine showed viral suppression comparable with those of other ...

Emma Rorison told her insurance firm employers Domestic and General she was undergoing cancer treatment and also had HIV, ...

Memphis ranked second in the country for new HIV infections among metropolitan areas in the United States, according to the ...